Date | Price Target | Rating | Analyst |
---|---|---|---|
2/1/2024 | $119.00 → $129.00 | Buy | Needham |
5/22/2023 | $140.00 | Buy | CL King |
3/27/2023 | $124.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
3/21/2023 | $96.00 | Equal Weight | Wells Fargo |
10/12/2022 | $85.00 | Hold | Jefferies |
3/2/2022 | $155.00 | Neutral | BofA Securities |
1/21/2022 | $158.00 → $150.00 | Buy | Needham |
10/28/2021 | $150.00 → $158.00 | Buy | Needham |
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $107 to $106.
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) with a Buy and maintains $107 price target.
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. CONMED The Trade: CONMED Corporation (NYSE:CNMD) Chief Operating Officer Pat Beyer acquired a total of 3,000 shares at an
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 8, 2024, payable on October 4, 2024, to all shareholders of record as of September 16, 2024. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based
CONMED Corporation (NYSE:CNMD) today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Sales of $332.1 million increased 4.5% year-over-year as reported and 5.2% in constant currency. Domestic revenue increased 6.1% year-over-year. International revenue increased 2.6% year-over-year as reported and 4.0% in constant currency. Diluted net earnings per share (GAAP) were $0.96 compared to diluted net earnings per share (GAAP) of $0.43 in the second quarter of 2023. Adjusted diluted net earnings per share(1) were $0.98, an increase of 18.1% compared to the second quarter of 2023. "Our second quarter and first half of 2024 p
CONMED Corporation (NYSE:CNMD) today announced it will report financial results for the second quarter of 2024 after the market close on Wednesday, July 31, 2024. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
8-K - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
10-Q - CONMED Corp (0000816956) (Filer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
3 - CONMED Corp (0000816956) (Issuer)
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am
CONMED Corporation (NYSE:CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the CL King 22nd Annual Best Ideas Conference at 10:15 a.m. ET on Monday, September 16, 2024. A live video webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.conmed.com and will be available for replay following the event. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by
CONMED Corporation (NYSE:CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Wednesday, September 4, 2024. A live webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.conmed.com and will be available for replay following the event. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other h
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 8, 2024, payable on October 4, 2024, to all shareholders of record as of September 16, 2024. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based
Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously
CL King initiated coverage of CONMED with a rating of Buy and set a new price target of $140.00
KeyBanc Capital Markets upgraded CONMED from Sector Weight to Overweight and set a new price target of $124.00
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)